home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409a.zip
/
M9490080.TXT
< prev
next >
Wrap
Text File
|
1994-09-03
|
2KB
|
29 lines
Document 0080
DOCN M9490080
TI Immunogenicity of hybrid hepatitis B surface antigen particles.
DT 9411
AU Mancini M; Schlienger K; Tiollais P; Michel ML; Unite de Recombinaison
et Expression Genetique, Institut; Pasteur, Paris, France.
SO Int Rev Immunol. 1994;11(2):143-51. Unique Identifier : AIDSLINE
MED/94321838
AB Hepatitis B surface antigen (HBsAg) produced by recombinant DNA
technology is now widely and safely used worldwide for hepatitis B
vaccination. We used the HBsAg particle as a carrier molecule for
presentation of selected human immunodeficiency virus type 1 (HIV-1)
determinants to the immune system. Immunization studies carried out in
primates showed that the particles elicit HIV specific virus
neutralizing antibodies as well as T cell proliferative responses to
both pathogens. As an experimental approach to active immunotherapy for
hepatitis B virus (HBV) chronic carriers, we evaluated the efficiency of
such hybrid antigen to overcome B cell tolerance in HBV transgenic mice.
DE Amino Acid Sequence Animal AIDS Vaccines/*IMMUNOLOGY Blotting,
Western Genetic Vectors/*IMMUNOLOGY Hepatitis B Surface
Antigens/*IMMUNOLOGY Hepatitis B Vaccines/*IMMUNOLOGY Molecular
Sequence Data Recombinant Fusion Proteins/*IMMUNOLOGY Support,
Non-U.S. Gov't T-Lymphocytes/IMMUNOLOGY Vaccines, Synthetic/IMMUNOLOGY
JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).